Tekturna HCT Treats Patients Not Meeting Blood Pressure Goals


July 22, 2009
Tekturna 300 mg tablets

Tekturna HCT (aliskiren and hydrochlorothiazide) tablets are indicated for an initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. It is a single-pill combination of Tekturna (aliskiren), the first approved direct renin inhibitor, and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly used high blood pressure medications.

Tekturna, a direct renin inhibitor, is the only drug that works by directly targeting renin and decreasing the activity of the RAAS. Renin is an enzyme produced by the kidneys that starts a process that makes blood vessels narrow and, when inappropriately activated, may lead to high blood pressure. Tekturna reduces renin activity and helps blood vessels relax and widen so blood pressure is lowered.

Tekturna HCT is available in four strengths as tablets containing aliskiren and hydrochlorothiazide: 150 mg/12.5 mg tablets, 150 mg/25 mg tablets, 300 mg/12.5 mg tablets and 300 mg/25 mg tablets.

For more information: www.novartis.com